Clinical trial
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV07/ ENGOT-ov80 Study)
NCT06023862 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV07/ ENGOT-ov80 Study)
- Lead sponsor
- Yonsei University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- January 22, 2024
- Completion date
- December 31, 2029
- Enrollment
- 198 (estimated)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.
clear cell carcinoma, endometrial neoplasms, ovarian neoplasms, uterine cervical neoplasms, vagina neoplasm, vulvar cancer